ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for ...
2020年9月1日 · ASLAN003 is a highly potent dihydroorotate dehydrogenase inhibitor that induces differentiation, as well as reduces cell proliferation and viability, of acute myeloid leukemia cell …
AML-003 vs AML-358 - YouTube
2020年5月12日 · This is the fight between Anomaly 003 and Anomaly 358!If you enjoy this video, smash that licktiy-like button for more contentsimilar to this, comment who yo...
LAM-003, a new drug for treatment of tyrosine kinase inhibitor ...
2019年11月26日 · Here we show that LAM-003, a prodrug of the heat shock protein 90 inhibitor LAM-003A, has cytotoxic activity against AML cell lines and primary samples harboring FLT3 …
LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor
2019年11月13日 · Here, we describe the nonclinical activity of LAM-003, an orally bioavailable HSP90 inhibitor (HSP90i) under clinical development for AML. To assess the anti-leukemic …
LAM-003，一种治疗酪氨酸激酶抑制剂耐药的FLT3-ITD阳性AML的 …
LAM-003在MV-4-11异种移植小鼠模型中使肿瘤消退，并在MOLM-13全身模型中延长了生存期。 LAM-003与化疗药物和FLT3抑制剂具有协同活性，使用BCL-2抑制剂Venetoclax可获得最强大 …
LAM-003, a new drug for treatment of tyrosine kinase inhibitor ...
The heat shock protein 90 inhibitor LAM-003 displays potent in vitro and in vivo activity as a single agent and combined with venetoclax. LAM-003 retains antileukemic activity against AML cells …
LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for …
2019年11月13日 · Here, we describe the nonclinical activity of LAM-003, an orally bioavailable HSP90 inhibitor (HSP90i) under clinical development for AML. To assess the anti-leukemic …
LAM-003, a new drug for treatment of tyrosine kinase inhibitor ...
2019年11月26日 · LAM-003 retains antileukemic activity against AML cells rendered resistant to FLT3 kinase inhibitors by mutation or stromal signaling. LAM-003 display antileukemic activity …
condary FLT3 mutations and protective stromal signaling within the bone marrow niche. Here we show that LAM-003, a prodrug of the heat shock protein 90 inhibitor LAM-003A, has cytotoxic …
We describe nonclinical studies of LAM-003, a novel, orally bioavailable HSP90 inhibitor prodrug, for the treatment of AML. BA/F3 cells (murine cell line dependent on growth factor or …